# Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung Cancer

> **NCT00932152** · PHASE2 · TERMINATED · sponsor: **University of Pittsburgh** · enrollment: 3 (actual)

## Conditions studied

- Non-small Cell Lung Cancer
- Postmenopausal Women

## Interventions

- **DRUG:** fulvestrant (Faslodex)
- **DRUG:** anastrozole (Arimidex)
- **DRUG:** Bevacizumab (Avastin)
- **DRUG:** Best supportive care

## Key facts

- **NCT ID:** NCT00932152
- **Lead sponsor:** University of Pittsburgh
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-09
- **Primary completion:** 2013-01
- **Final completion:** 2013-01
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Poor enrollment/suspended to accrual; will close per AstraZeneca request
- **Last updated:** 2017-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00932152

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00932152, "Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00932152. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*